Do Kim
Stock Analyst at Piper Sandler
(1.97)
# 2,808
Out of 4,831 analysts
98
Total ratings
44%
Success rate
0.54%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $32.53 | +93.67% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $20.94 | +119.68% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $432.00 | -31.48% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $101.43 | +10.42% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $23.76 | +266.16% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.56 | +798.44% | 2 | Jan 19, 2023 | |
| AFMD Affimed | Maintains: Overweight | $70 → $60 | $0.13 | +44,676.12% | 6 | Dec 12, 2022 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $18.29 | +9.35% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $7.41 | +480.30% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $36.95 | -13.40% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $2.10 | +947.62% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $31.40 | -39.49% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.19 | +630.59% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $266.86 | -30.68% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $11.40 | +7,794.74% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $50.23 | -30.32% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.00 | +1,900.00% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $32.53
Upside: +93.67%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $20.94
Upside: +119.68%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $432.00
Upside: -31.48%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $101.43
Upside: +10.42%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $23.76
Upside: +266.16%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.56
Upside: +798.44%
Affimed
Dec 12, 2022
Maintains: Overweight
Price Target: $70 → $60
Current: $0.13
Upside: +44,676.12%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $18.29
Upside: +9.35%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $7.41
Upside: +480.30%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $36.95
Upside: -13.40%
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $2.10
Upside: +947.62%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $31.40
Upside: -39.49%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.19
Upside: +630.59%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $266.86
Upside: -30.68%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $11.40
Upside: +7,794.74%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $50.23
Upside: -30.32%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.00
Upside: +1,900.00%